All In Biotech

Drug Trial Radar · NCT06298071

A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.

A Phase Ib Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Characteristics, and Initial Efficacy of Single and Multiple Dosing of Peguricase for Injection With Methotrexate in Patients With Gout.

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Mar 3, 2023

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
Collaborators
The First Affiliated Hospital of Bengbu Medical University; The First Affiliated Hospital of Henan University of Science and Technology
First posted
Mar 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of peguricase for injection with methotrexate in patients with gout who remain uncontrolled after standardized treatment with conventional uric acid-lowering drugs, to determine the recommended dose for phase II clinical trials, and to provide basis for formulation of administration regimen for phase II clinical trials.

Conditions

  • Gout

Interventions

  • SIBP-R002Drug

    Injection; strength: 4mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.

  • SIBP-R002Drug

    Injection; strength: 8mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.

  • SIBP-R002Drug

    Injection; strength: 12mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.

  • MethotrexateDrug

    Combination drugs: Methotrexate, dose15 mg, oral.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AE(Adverse Events)Time frame: 14 weeks after the first dose
  2. SAE(Serious Adverse Events)Time frame: 14 weeks after the first dose
  3. AUC(Area Under The Plasma Concentration Versus Time Curve)Time frame: 14 weeks after the first dose
  4. Cmax(Peak Plasma Concentration)Time frame: 14 weeks after the first dose
  5. Tmax(Peak Time)Time frame: 14 weeks after the first dose
  6. T ½ (Terminal elimination half-life)Time frame: 14 weeks after the first dose
  7. CL (Clearance Rate)Time frame: 14 weeks after the first dose
  8. ADA (Anti-uricase Antibody, Anti-PEG Antibody, Anti-PEG-uricase Antibody)Time frame: 14 weeks after the first dose
  9. NAb (Anti-PEG-uricase Neutralizing Antibody)Time frame: 14 weeks after the first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.